A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM).
Phase of Trial: Phase II/III
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Pemetrexed
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms MAPS
- 05 Jun 2018 Results assessing health-related quality of life, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 01 Sep 2016 Status changed from active, no longer recruiting to completed.
- 09 Mar 2016 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History